We're planning to convert whole Korean cancer patients data into CDM from National Insurance data of HIRA (Korean national insurance data covers almost 99% population of Korea. This insurance covers 95% of cancer-related claim (If the patients should pay 100$ for the treatment, it covers 95$). Then, we can run @rchen 's treatment pattern in cancer patient on much bigger data.
We'll perform descriptive analysis about incidence, overall survival and the whole cost within 1, 3 and 5 years after diagnosing of cancer in each age/gender group.
If other sites can participate, we compare the incidence, survival and the cost information year by year across the countries. The novel drug continues to be developed in oncology. Usually, these novel drugs are introduced in Korea 1~2 years after approval of American FDA. I want to answer to this question: "Does new drug or money cure more patients than health system?". The health system can include early screening strategy of the country, insurance system, novel drug approval system, and other health-related situation such as obesity prevalence, air pollution, and etc.
Because I'm not the expert on the economic research, I need the help @Gowtham_Rao.
And I need to listen your thoughts, @rchen @Christian_Reich @mgurley @Patrick_Ryan @hripcsa